MA58087B1 - Nouveaux dérivés de méthylquinazolinone - Google Patents
Nouveaux dérivés de méthylquinazolinoneInfo
- Publication number
- MA58087B1 MA58087B1 MA58087A MA58087A MA58087B1 MA 58087 B1 MA58087 B1 MA 58087B1 MA 58087 A MA58087 A MA 58087A MA 58087 A MA58087 A MA 58087A MA 58087 B1 MA58087 B1 MA 58087B1
- Authority
- MA
- Morocco
- Prior art keywords
- methylquinazolinone
- derivatives
- new
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Harvester Elements (AREA)
- Combines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
| EP20817377.3A EP4073065B1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA58087B1 true MA58087B1 (fr) | 2025-04-30 |
Family
ID=68848113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA58087A MA58087B1 (fr) | 2019-12-10 | 2020-12-08 | Nouveaux dérivés de méthylquinazolinone |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (OSRAM) |
| EP (2) | EP4483882A3 (OSRAM) |
| JP (2) | JP7108146B2 (OSRAM) |
| KR (1) | KR102836833B1 (OSRAM) |
| CN (2) | CN114787156B (OSRAM) |
| AR (1) | AR122351A1 (OSRAM) |
| AU (1) | AU2020403443B2 (OSRAM) |
| CA (1) | CA3162883A1 (OSRAM) |
| CL (1) | CL2022001529A1 (OSRAM) |
| CO (1) | CO2022008968A2 (OSRAM) |
| CR (1) | CR20220251A (OSRAM) |
| DK (1) | DK4073065T3 (OSRAM) |
| ES (1) | ES3023264T3 (OSRAM) |
| FI (1) | FI4073065T3 (OSRAM) |
| HR (1) | HRP20250418T1 (OSRAM) |
| HU (1) | HUE071148T2 (OSRAM) |
| IL (2) | IL292161B2 (OSRAM) |
| LT (1) | LT4073065T (OSRAM) |
| MA (1) | MA58087B1 (OSRAM) |
| MX (1) | MX2022006783A (OSRAM) |
| NZ (1) | NZ787393A (OSRAM) |
| PE (1) | PE20221778A1 (OSRAM) |
| PH (1) | PH12022551119A1 (OSRAM) |
| PL (1) | PL4073065T3 (OSRAM) |
| PT (1) | PT4073065T (OSRAM) |
| RS (1) | RS66721B1 (OSRAM) |
| SI (1) | SI4073065T1 (OSRAM) |
| TW (1) | TWI877268B (OSRAM) |
| UA (1) | UA128299C2 (OSRAM) |
| WO (1) | WO2021116055A1 (OSRAM) |
| ZA (2) | ZA202204675B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4073065T3 (pl) | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe pochodne metylochinazolinonu |
| PL4073044T3 (pl) * | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe inhibitory BRAF jako związki przełamujące paradoks |
| PE20231651A1 (es) | 2020-06-09 | 2023-10-17 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| MX2023014565A (es) * | 2021-06-09 | 2024-02-08 | Chugai Pharmaceutical Co Ltd | Tratamiento conjunto para tratamiento contra el cancer. |
| CA3216220A1 (en) * | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| TW202313589A (zh) * | 2021-06-09 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | （３ｒ）－ｎ－〔２－氰基－４－氟－３－（－３－甲基－４－側氧－喹唑啉－６－基）氧－苯基〕－３－氟－吡咯啶－１－磺醯胺之新穎固體形式 |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| CA3230652A1 (en) | 2021-11-04 | 2023-05-11 | F. Hoffmann-La Roche Ag | Novel use of quinazolinone compound for the treatment of cancer |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| EP4618994A1 (en) | 2022-11-18 | 2025-09-24 | F. Hoffmann-La Roche AG | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
| TW202438072A (zh) * | 2022-12-15 | 2024-10-01 | 瑞士商赫孚孟拉羅股份公司 | 製備喹唑啉酮衍生物之方法 |
| CN120359214A (zh) * | 2022-12-15 | 2025-07-22 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的组合疗法 |
| WO2025008313A1 (en) | 2023-07-04 | 2025-01-09 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025153057A1 (zh) * | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| PT2947072T (pt) | 2008-03-17 | 2016-12-06 | Ambit Biosciences Corp | 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| CA2882410A1 (en) | 2012-09-19 | 2014-03-27 | Novartis Ag | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
| RU2015149937A (ru) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | Соединения для модулирования киназы и показания к их применению |
| CN113893253A (zh) | 2015-05-22 | 2022-01-07 | 普莱希科公司 | 用于治疗braf-v600相关的疾病的plx-8394或plx-7904 |
| TWI720032B (zh) | 2015-10-09 | 2021-03-01 | 比利時商葛萊伯格有限公司 | Ｎ－磺醯化吡唑并﹝３，４－ｂ﹞吡啶－６－甲醯胺及其使用方法 |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| JP7539892B2 (ja) | 2019-01-03 | 2024-08-26 | ジェネンテック， インコーポレイテッド | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PL4073044T3 (pl) * | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe inhibitory BRAF jako związki przełamujące paradoks |
| PL4073065T3 (pl) * | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe pochodne metylochinazolinonu |
| PE20231651A1 (es) | 2020-06-09 | 2023-10-17 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf |
| WO2022129260A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New aryl-pyrido-pyrimidin-one derivatives |
| EP4263518A1 (en) | 2020-12-18 | 2023-10-25 | F. Hoffmann-La Roche AG | New quinazolinone derivatives |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| AU2022403854B2 (en) | 2021-12-08 | 2025-04-17 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
-
2020
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/en active Pending
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 NZ NZ787393A patent/NZ787393A/en unknown
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/en active Active
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 CA CA3162883A patent/CA3162883A1/en active Pending
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/en not_active Ceased
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
-
2021
- 2021-12-14 JP JP2021202780A patent/JP2022124458A/ja active Pending
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA58087B1 (fr) | Nouveaux dérivés de méthylquinazolinone | |
| MA52948B1 (fr) | Composés | |
| MA46337A (fr) | Composé de pyridine | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| CR20200588A (es) | Compuestos novedosos | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA38472A1 (fr) | Composé peptidique | |
| MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| MA42341B2 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| MA39983B1 (fr) | Dérivés de carboxamide | |
| MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
| EA202192760A1 (ru) | Трициклические соединения | |
| FR3064634B1 (fr) | Derives acryliques de 1 :4, 3 :6 dianhydrohexitol | |
| MA40605B1 (fr) | Composé pyrazolothiazole et médicament |